Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.

Gentilini LD, Jaworski FM, Tiraboschi C, Pérez IG, Kotler ML, Chauchereau A, Laderach DJ, Compagno D.

Oncotarget. 2017 Jul 4;8(27):44654-44668. doi: 10.18632/oncotarget.17963.

2.

In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development.

Jaworski FM, Gentilini LD, Gueron G, Meiss RP, Ortiz EG, Berguer PM, Ahmed A, Navone N, Rabinovich GA, Compagno D, Laderach DJ, Vazquez ES.

Clin Cancer Res. 2017 Sep 1;23(17):5135-5148. doi: 10.1158/1078-0432.CCR-17-0112. Epub 2017 May 16.

PMID:
28512172
3.

Glycans and galectins in prostate cancer biology, angiogenesis and metastasis.

Compagno D, Gentilini LD, Jaworski FM, Pérez IG, Contrufo G, Laderach DJ.

Glycobiology. 2014 Oct;24(10):899-906. doi: 10.1093/glycob/cwu055. Epub 2014 Jun 16.

PMID:
24939371
4.

Galectins: major signaling modulators inside and outside the cell.

Compagno D, Jaworski FM, Gentilini L, Contrufo G, González Pérez I, Elola MT, Pregi N, Rabinovich GA, Laderach DJ.

Curr Mol Med. 2014;14(5):630-51. Review.

PMID:
24894174
5.

Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers.

Laderach DJ, Gentilini L, Jaworski FM, Compagno D.

Prostate Cancer. 2013;2013:519436. doi: 10.1155/2013/519436. Epub 2013 Sep 24. Review.

6.

Delineating the "galectin signature" of the tumor microenvironment.

Compagno D, Laderach DJ, Gentilini L, Jaworski FM, Rabinovich GA.

Oncoimmunology. 2013 Apr 1;2(4):e23565.

Supplemental Content

Loading ...
Support Center